Eli Lilly Obesity Drug Yields 28% Loss

Eli Lilly shares rose ~2% in pre‑market trading after reporting late‑stage trial results for obesity drug retatrutide.
The trial showed a 12‑mg dose led to average 28.3% weight loss over 80 weeks, with >45% losing ≥30% weight.
Retatrutide activates GLP‑1, GIP and glucagon receptors, offering greater weight loss than Lilly’s Zepbound and Novo Nordisk’s Wegovy.
President Kenneth Custer said 30% weight loss matches bariatric surgery thresholds, marking a potentially major medical breakthrough.